{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T11:19:11Z","timestamp":1765711151666,"version":"3.48.0"},"reference-count":14,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2013,12,15]]},"published-print":{"date-parts":[[2014,6]]},"abstract":"\n Aims<\/jats:title>\n Human papillomavirus (HPV) testing is more sensitive than cytology for detection of residual\/recurrent cervical disease after lesion treatment. Several HPV test comparison studies have been performed within triage and screening populations, but data on their comparative performance in a test of cure context is lacking. This study aims to address this gap.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We compared the technical and clinical performance of Abbott RealTi\n m<\/jats:italic>\n e High risk (HR)-HPV, Genprobe Aptima PV, Hologic Cervista HPV-HR, Qiagen Hybrid Capture 2 and Roche cobas HPV in the Early Implementation phase of a \u2018test of cure\u2019 service within the Scottish Cervical Screening Programme.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Valid results with all five HPV Tests from 1020 first samples taken \u223c6\u2005months post-treatment showed HPV positivity ranging from 17.84% to 26.96%. There was perfect agreement in 74%, and greatest variation between assays was observed in cytologically negative samples. Clinical performance was judged on cumulative incidence of cervical intraepithelial neoplasia 2+ (CIN2+) during follow-up (mean: 13.2\u2005months). There were 23 cases of CIN2+ of which 14 were CIN3+. All assays, including cytology, were 100% sensitive for detection of CIN3+. Of the nine cases of residual CIN2, three assays detected all, one assay missed one and one assay missed two cases. Specificity ranged from 75% to 84% according to assay.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n All assays were sensitive for detection of CIN2+ at 6\u2005months post-treatment. The range of positivity equated to a 50% increase between assays with the lowest and highest positivity rates. The relevance of HPV positivity in the absence of cytological abnormalities requires longer follow-up to determine whether additional tools for risk stratification are required.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/jclinpath-2013-202014","type":"journal-article","created":{"date-parts":[[2014,1,16]],"date-time":"2014-01-16T22:22:23Z","timestamp":1389910943000},"page":"458-463","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H)"],"prefix":"10.1136","volume":"67","author":[{"given":"H A","family":"Cubie","sequence":"first","affiliation":[{"name":"HPV Research Group, University of Edinburgh MRC Centre for Reproductive Health, Queen's Medical Research Institute, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Canham","sequence":"additional","affiliation":[{"name":"HPV Research Group, University of Edinburgh MRC Centre for Reproductive Health, Queen's Medical Research Institute, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Moore","sequence":"additional","affiliation":[{"name":"Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Pedraza","sequence":"additional","affiliation":[{"name":"HPV Research Group, University of Edinburgh MRC Centre for Reproductive Health, Queen's Medical Research Institute, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Graham","sequence":"additional","affiliation":[{"name":"Wellcome Trust Clinical Research Facility, University of Edinburgh, Western General Hospital, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Cuschieri","sequence":"additional","affiliation":[{"name":"Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,1,16]]},"reference":[{"key":"2025121403141564000_67.6.458.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.095"},{"key":"2025121403141564000_67.6.458.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70078-X"},{"key":"2025121403141564000_67.6.458.3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1386-6532(09)00540-X","article-title":"Validation of high-risk HPV tests for primary cervical screening","volume":"S3","author":"Meijer","year":"2009","journal-title":"J Clin Virol"},{"key":"2025121403141564000_67.6.458.4","unstructured":"Cubie HA Cuschieri K . Understanding HPV tests and their appropriate applications. Cytopathology 2013.doi:10\/1111\/cyt.12083. [Epub ahead of print]."},{"key":"2025121403141564000_67.6.458.5","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-08-0508"},{"key":"2025121403141564000_67.6.458.6","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00181-12"},{"key":"2025121403141564000_67.6.458.7","unstructured":"Scottish Cervical Screening Programme. Cervical Screening-changes to screening test result categories. http:\/\/www.nsd.scot.nhs.uk\/services\/screening\/cervicalscreening\/ (accessed 4 Oct 2013)."},{"key":"2025121403141564000_67.6.458.8","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00896-09"},{"key":"2025121403141564000_67.6.458.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.07.033"},{"key":"2025121403141564000_67.6.458.10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ajog.2008.11.031","article-title":"Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review","volume":"200","author":"Chan","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"2025121403141564000_67.6.458.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.05.002"},{"key":"2025121403141564000_67.6.458.12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21604"},{"key":"2025121403141564000_67.6.458.13","unstructured":"NHS Cancer Screening programmes. HPV triage and test of cure in the cervical screening programme in England. http:\/\/www.cancerscreening.nhs.uk\/cervical\/hpv-triage-test-of-cure.html (accessed 4 Oct 2013)."},{"key":"2025121403141564000_67.6.458.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7086"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2013-202014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T11:14:24Z","timestamp":1765710864000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2013-202014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,16]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,5,17]]},"published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1136\/jclinpath-2013-202014"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2013-202014","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"type":"print","value":"0021-9746"},{"type":"electronic","value":"1472-4146"}],"subject":[],"published":{"date-parts":[[2014,1,16]]}}}